
T2 Biosystems TTOO
Quarterly report 2024-Q3
added 11-14-2024
T2 Biosystems Gross Profit 2011-2026 | TTOO
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit T2 Biosystems
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -3.15 M | -8.43 M | -4.9 M | -7.36 M | -2.79 M | 1.07 M | - | 266 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.07 M | -8.43 M | -3.61 M |
Gross Profit of other stocks in the Diagnostics research industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
17.2 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
2.84 B | $ 113.86 | -0.85 % | $ 34.6 B | ||
|
Danaher Corporation
DHR
|
14.5 B | $ 190.59 | -0.8 % | $ 136 B | ||
|
DexCom
DXCM
|
2.8 B | $ 63.64 | 0.68 % | $ 24.8 B | ||
|
Fulgent Genetics
FLGT
|
107 M | $ 16.32 | -0.61 % | $ 493 M | ||
|
Guardant Health
GH
|
144 M | $ 90.59 | 1.04 % | $ 11.4 B | ||
|
ICON Public Limited Company
ICLR
|
817 M | $ 107.81 | -1.66 % | $ 8.89 B | ||
|
Illumina
ILMN
|
2.86 B | $ 127.23 | -0.4 % | $ 20.2 B | ||
|
CareDx, Inc
CDNA
|
81.6 M | $ 17.63 | -1.07 % | $ 939 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
54.4 M | - | - | $ 562 M | ||
|
Laboratory Corporation of America Holdings
LH
|
4.01 B | $ 274.85 | 0.14 % | $ 22.9 B | ||
|
Lantheus Holdings
LNTH
|
942 M | $ 75.68 | -0.28 % | $ 5.11 B | ||
|
Akumin
AKU
|
53.5 M | - | -17.87 % | $ 25.9 M | ||
|
Medpace Holdings
MEDP
|
246 M | $ 493.63 | -0.48 % | $ 14.2 B | ||
|
Burning Rock Biotech Limited
BNR
|
364 M | $ 16.99 | 4.23 % | $ 176 M | ||
|
Myriad Genetics
MYGN
|
577 M | $ 4.62 | -1.07 % | $ 428 M | ||
|
Co-Diagnostics
CODX
|
400 K | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
NeoGenomics
NEO
|
314 M | $ 7.98 | -0.5 % | $ 1.02 B | ||
|
Aspira Women's Health
AWH
|
5.92 M | - | -6.19 % | $ 10.5 M | ||
|
Neogen Corporation
NEOG
|
421 M | $ 9.93 | 3.82 % | $ 2.15 B | ||
|
Natera
NTRA
|
127 M | $ 207.69 | 1.38 % | $ 20.4 B | ||
|
Accelerate Diagnostics
AXDX
|
842 K | - | -61.36 % | $ 2.46 M | ||
|
National Research Corporation
NRC
|
81.5 M | $ 17.24 | -0.52 % | $ 386 M | ||
|
Pacific Biosciences of California
PACB
|
45.8 M | $ 1.4 | -1.76 % | $ 420 M | ||
|
Global Cord Blood Corporation
CO
|
1.06 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
83.3 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-251 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
281 M | - | 0.12 % | $ 80.1 M | ||
|
Precipio
PRPO
|
10.7 M | $ 26.0 | 0.08 % | $ 41.7 M | ||
|
Personalis
PSNL
|
22.1 M | $ 6.21 | -5.57 % | $ 368 M | ||
|
Charles River Laboratories International
CRL
|
958 M | $ 167.8 | -0.25 % | $ 8.32 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
869 M | - | - | $ 10.7 B | ||
|
Sotera Health Company
SHC
|
646 M | $ 14.86 | -0.1 % | $ 4.22 B | ||
|
Castle Biosciences
CSTL
|
53 M | $ 24.96 | 0.93 % | $ 693 M | ||
|
Soleno Therapeutics
SLNO
|
-58.5 K | $ 52.25 | - | $ 2.66 B | ||
|
Biocept
BIOC
|
6.12 M | - | -13.05 % | $ 7.29 M | ||
|
Neuronetics
STIM
|
72.3 M | $ 1.6 | -9.09 % | $ 106 M | ||
|
Biodesix
BDSX
|
18.5 M | $ 14.71 | -4.21 % | $ 1.91 B | ||
|
Koninklijke Philips N.V.
PHG
|
8.06 B | $ 26.99 | -0.79 % | $ 20 B | ||
|
Thermo Fisher Scientific
TMO
|
11.3 B | $ 483.56 | -0.95 % | $ 182 B | ||
|
Trinity Biotech plc
TRIB
|
21.4 M | $ 0.61 | -1.34 % | $ 61.9 M | ||
|
Waters Corporation
WAT
|
1.4 B | $ 301.9 | -0.72 % | $ 18 B | ||
|
QIAGEN N.V.
QGEN
|
1.3 B | - | - | $ 10.6 B | ||
|
Anixa Biosciences
ANIX
|
83.8 K | $ 2.59 | - | $ 84.1 K | ||
|
Biomerica
BMRA
|
498 K | $ 2.08 | -4.13 % | $ 4.78 M | ||
|
BioNano Genomics
BNGO
|
2.77 M | $ 1.14 | -1.3 % | $ 6.21 M | ||
|
Interpace Biosciences
IDXG
|
24.1 M | $ 2.02 | 2.54 % | $ 8.94 M |